TENX
Tenax Therapeutics, Inc.
Biotechnology
Market Cap$69M
5Y Perf.-99.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TENX vs PRTA
Revenue, margins, valuation, and 5-year total return — side by side.
PRTA
Prothena Corporation plc
Biotechnology
Market Cap$567M
5Y Perf.-1.2%
TENX vs PRTA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TENX | PRTA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $69M | $567M |
| Revenue (TTM) | $0.00 | $58M |
| Net Income (TTM) | $-43M | $-151M |
| Gross Margin | — | -39.7% |
| Operating Margin | — | -210.6% |
| Forward P/E | — | 42.7x |
| Total Debt | $0.00 | $14M |
| Cash & Equiv. | $95M | $308M |
TENX vs PRTA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TENX
PRTA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Tenax Therapeutics,… (TENX) | 100 | 0.5 | -99.5% |
| Prothena Corporatio… (PRTA) | 100 | 98.8 | -1.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TENX vs PRTA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TENX leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
TENX
Tenax Therapeutics, Inc.
The Income Pick
TENX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.90
- EPS growth 96.3%
- Lower volatility, beta 0.90, current ratio 20.60x
Best for: income & stability and growth exposure
PRTA
Prothena Corporation plc
The Long-Run Compounder
PRTA is the clearest fit if your priority is long-term compounding.
- -73.0% 10Y total return vs TENX's -100.0%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TENX | 428.0% revenue growth vs PRTA's -92.8% |
| Quality / Margins | TENX | 2.0% margin vs PRTA's -260.9% |
| Stability / Safety | TENX | Beta 0.90 vs PRTA's 0.96 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TENX | +109.2% vs PRTA's +44.4% |
| Efficiency (ROA) | TENX | -42.1% ROA vs PRTA's -42.3% |
TENX vs PRTA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2013
FY 2025
TENX vs PRTA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTENXLAGGINGPRTA
PRTAProthena Corporation …
1leads
TENXTenax Therapeutics, I…
2leads
6 Total Categories
CATEGORYLEADERvs PRTAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PRTA1/1
Valuation MetricsMultiples, price ratios, and targets
TENX2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TENX5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PRTA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
PRTA and TENX operate at a comparable scale, with $58M and $0 in trailing revenue.
| Metric | TENXTenax Therapeutic… | PRTAProthena Corporat… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $58M |
| EBITDAEarnings before interest/tax | -$43M | -$121M |
| Net IncomeAfter-tax profit | -$43M | -$151M |
| Free Cash FlowCash after capex | -$26M | -$85M |
| Gross MarginGross profit ÷ Revenue | — | -39.7% |
| Operating MarginEBIT ÷ Revenue | — | -2.1% |
| Net MarginNet income ÷ Revenue | — | -2.6% |
| FCF MarginFCF ÷ Revenue | — | -147.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +17.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -110.5% | +153.6% |
PRTA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
TENX leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | TENXTenax Therapeutic… | PRTAProthena Corporat… |
|---|---|---|
| Market CapShares × price | $69M | $567M |
| Enterprise ValueMkt cap + debt − cash | -$26M | $273M |
| Trailing P/EPrice ÷ TTM EPS | -10.13x | -2.32x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 42.68x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 58.54x |
| Price / BookPrice ÷ Book value/share | 1.93x | 2.02x |
| Price / FCFMarket cap ÷ FCF | — | — |
TENX leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
TENX leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
TENX delivers a -45.0% return on equity — every $100 of shareholder capital generates $-45 in annual profit, vs $-50 for PRTA. On the Piotroski fundamental quality scale (0–9), TENX scores 3/9 vs PRTA's 1/9, reflecting mixed financial health.
| Metric | TENXTenax Therapeutic… | PRTAProthena Corporat… |
|---|---|---|
| ROE (TTM)Return on equity | -45.0% | -49.9% |
| ROA (TTM)Return on assets | -42.1% | -42.3% |
| ROICReturn on invested capital | — | -21.0% |
| ROCEReturn on capital employed | -39.0% | -47.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 1 |
| Debt / EquityFinancial leverage | — | 0.05x |
| Net DebtTotal debt minus cash | -$95M | -$294M |
| Cash & Equiv.Liquid assets | $95M | $308M |
| Total DebtShort + long-term debt | $0 | $14M |
| Interest CoverageEBIT ÷ Interest expense | -847.57x | — |
TENX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — TENX and PRTA each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRTA five years ago would be worth $4,277 today (with dividends reinvested), compared to $35 for TENX. Over the past 12 months, TENX leads with a +109.2% total return vs PRTA's +44.4%. The 3-year compound annual growth rate (CAGR) favors TENX at -23.4% vs PRTA's -48.5% — a key indicator of consistent wealth creation.
| Metric | TENXTenax Therapeutic… | PRTAProthena Corporat… |
|---|---|---|
| YTD ReturnYear-to-date | +5.4% | +14.5% |
| 1-Year ReturnPast 12 months | +109.2% | +44.4% |
| 3-Year ReturnCumulative with dividends | -55.1% | -86.3% |
| 5-Year ReturnCumulative with dividends | -99.6% | -57.2% |
| 10-Year ReturnCumulative with dividends | -100.0% | -73.0% |
| CAGR (3Y)Annualised 3-year return | -23.4% | -48.5% |
Evenly matched — TENX and PRTA each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TENX and PRTA each lead in 1 of 2 comparable metrics.
Risk & Volatility
TENX is the less volatile stock with a 0.90 beta — it tends to amplify market swings less than PRTA's 0.96 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRTA currently trades 90.1% from its 52-week high vs TENX's 63.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TENXTenax Therapeutic… | PRTAProthena Corporat… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.90x | 0.96x |
| 52-Week HighHighest price in past year | $18.38 | $11.69 |
| 52-Week LowLowest price in past year | $5.34 | $4.32 |
| % of 52W HighCurrent price vs 52-week peak | +63.4% | +90.1% |
| RSI (14)Momentum oscillator 0–100 | 38.4 | 60.3 |
| Avg Volume (50D)Average daily shares traded | 520K | 474K |
Evenly matched — TENX and PRTA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | TENXTenax Therapeutic… | PRTAProthena Corporat… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $19.00 |
| # AnalystsCovering analysts | — | 28 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
TENX leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). PRTA leads in 1 (Income & Cash Flow). 2 tied.
Best OverallTenax Therapeutics, Inc. (TENX)Leads 2 of 6 categories
Loading custom metrics...
TENX vs PRTA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TENX or PRTA a better buy right now?
Analysts rate Prothena Corporation plc (PRTA) a "Buy" — based on 28 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TENX or PRTA?
Over the past 5 years, Prothena Corporation plc (PRTA) delivered a total return of -57.
2%, compared to -99. 6% for Tenax Therapeutics, Inc. (TENX). Over 10 years, the gap is even starker: PRTA returned -73. 0% versus TENX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TENX or PRTA?
By beta (market sensitivity over 5 years), Tenax Therapeutics, Inc.
(TENX) is the lower-risk stock at 0. 90β versus Prothena Corporation plc's 0. 96β — meaning PRTA is approximately 7% more volatile than TENX relative to the S&P 500.
04Which is growing faster — TENX or PRTA?
On earnings-per-share growth, the picture is similar: Tenax Therapeutics, Inc.
grew EPS 96. 3% year-over-year, compared to -99. 6% for Prothena Corporation plc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TENX or PRTA?
Tenax Therapeutics, Inc.
(TENX) is the more profitable company, earning 0. 0% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TENX leads at 0. 0% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — PRTA leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TENX or PRTA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TENX or PRTA better for a retirement portfolio?
For long-horizon retirement investors, Tenax Therapeutics, Inc.
(TENX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90)). Both have compounded well over 10 years (TENX: -100. 0%, PRTA: -73. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TENX and PRTA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.